The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.